Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 849051, 8 pages
http://dx.doi.org/10.1155/2009/849051
Review Article

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Oncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, Italy

Received 12 January 2009; Accepted 7 April 2009

Academic Editor: Minesh Mehta

Copyright © 2009 Monica Giovannini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [25 citations]

The following is the list of published articles that have cited the current article.

  • Matthias Peipp, Michael Dechant, and Thomas Valerius, “Sensitivity and resistance to EGF-R inhibitors: Approaches to enhance the efficacy of EGF-R antibodies,” mAbs, vol. 1, no. 6, pp. 590–599, 2009. View at Publisher · View at Google Scholar
  • Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarico, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture, “Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients,” Clinical Cancer Research, vol. 16, no. 17, pp. 4452–4460, 2010. View at Publisher · View at Google Scholar
  • James E. Frampton, “Cetuximab A Review of its Use in Squamous Cell Carcinoma of the Head and Neck,” Drugs, vol. 70, no. 15, pp. 1987–2010, 2010. View at Publisher · View at Google Scholar
  • J. P. Agarwal, T. Gupta, N. Kalyani, A. Budrukkar, S. G. Laskar, V Murthy, P. Kumar, V Narohna, P. Pai, P. Chaturvedi, and A. K. D'cruz, “Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?,” Indian Journal Of Cancer, vol. 48, no. 2, pp. 148–153, 2011. View at Publisher · View at Google Scholar
  • Muhammad Wasif Saif, “Capecitabine and hand-foot syndrome,” Expert Opinion on Drug Safety, vol. 10, no. 2, pp. 159–169, 2011. View at Publisher · View at Google Scholar
  • Hsien-Ching Chiu, Fu-Chang Hu, Chih-Chieh Chan, Yi-Hua Liao, Hsiao-Chin Chen, Chia-Yu Chu, Shiou-Han Wang, and Chih-Hsin Yang, “Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan,” Dermatologica Sinica, vol. 29, no. 1, pp. 13–18, 2011. View at Publisher · View at Google Scholar
  • James E. Frampton, “Spotlight on cetuximab in squamous cell carcinoma of the head and neck,” BioDrugs, vol. 25, no. 2, pp. 129–133, 2011. View at Publisher · View at Google Scholar
  • E. Schott, M. P. Ebert, and J. Trojan, “Treatment of Hepatocellular Carcinoma with Sorafenib - Focus on Special Populations and Adverse Event Management,” Zeitschrift Fur Gastroenterologie, vol. 50, no. 9, pp. 1018–1027, 2012. View at Publisher · View at Google Scholar
  • Marye J. Boers-Sonderen, Ingrid M. Desar, Willeke Blokx, Johanna N. Timmer-Bonte, and Carla M. van Herpen, “A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244),” Anti-Cancer Drugs, vol. 23, no. 7, pp. 761–764, 2012. View at Publisher · View at Google Scholar
  • Sumit Paliwal, Byeong Hee Hwang, Kenneth Y. Tsai, and Samir Mitragotri, “Diagnostic opportunities based on skin biomarkers,” European Journal of Pharmaceutical Sciences, 2012. View at Publisher · View at Google Scholar
  • Christian Rolfo, Giuseppe Bronte, Francesco Passiglia, Konstantinos Papadimitriou, Antonio Russo, and Marc Peeters, “Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer,” Current Colorectal Cancer Reports, 2013. View at Publisher · View at Google Scholar
  • Riccardo Ricotta, Angelo Vanzulli, Mauro Moroni, Barbara Colnago, Matteo Oriani, Michele Nichelatti, Carolina Sarnataro, Filippo Venturini, Sara Di Bella, Martina Maiolani, Maria Olga Giganti, Andrea Sartore-Bianchi, and Salvatore Siena, “Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab,” Clinical Colorectal Cancer, vol. 12, no. 1, pp. 45–53, 2013. View at Publisher · View at Google Scholar
  • Julie Bogaert, Pieter-Jan Cuyle, and Eric Van Cutsempp. 139–161, 2013. View at Publisher · View at Google Scholar
  • Hsien-Yi Chiu, “Scalp Pustules in a Patient Receiving Chemotherapy,” Jama-Journal Of The American Medical Association, vol. 310, no. 10, pp. 1068–1069, 2013. View at Publisher · View at Google Scholar
  • Marye J. Boers-Sonderen, Carla M. L. van Herpen, Winette T. A. van der Graaf, Ingrid M. E. Desar, Mirjam G. W. Arens- van der Logt, Yvo M. de Beer, Petronella B. Ottevanger, and Nielka P. van Erp, “Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®),” Cancer Chemotherapy and Pharmacology, 2014. View at Publisher · View at Google Scholar
  • A. Scott, W. A. Messersmith, A. Jimeno, and S. L. Davis, “Panitumumab In The Treatment Of Colon Cancer: A Biomarker Dilemma,” Drugs of Today, vol. 50, no. 10, pp. 679–690, 2014. View at Publisher · View at Google Scholar
  • Brian Quigley, Steve Ducker, and Farah Khalilpp. 75–118, 2014. View at Publisher · View at Google Scholar
  • B. Melosky, N. B. Leighl, J. Rothenstein, R. Sangha, D. Stewart, and K. Papp, “Management of EGFR TKI-induced dermatologic adverse events,” Current Oncology, vol. 22, no. 2, pp. 123–132, 2015. View at Publisher · View at Google Scholar
  • Xavier Durando, Florence Dalenc, Catherine Abrial, Marie-Ange Mouret-Reynier, Pauline Herviou, Fabrice Kwiatkowski, Philippe Chollet, Henri Roche, and Emilie Thivat, “Neurotoxicity as a Prognostic Factor in Patients with Metastatic Breast Cancer Treated with Ixabepilone as a First-Line Therapy,” Oncology, vol. 88, no. 3, pp. 180–188, 2015. View at Publisher · View at Google Scholar
  • Franky Chandra, Dendi Sandiono, Unwati Sugiri, Oki Suwarsa, and Hendra Gunawan, “Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients,” Dermatology and Therapy, 2016. View at Publisher · View at Google Scholar
  • Hyunbo Shim, “Therapeutic antibodies by phage display,” Current Pharmaceutical Design, vol. 22, no. 43, pp. 6538–6559, 2016. View at Publisher · View at Google Scholar
  • Shoichi Watanabe, Hiroki Takahashi, Masayasu Hara, Daisuke Kawakita, Akimichi Morita, Motoki Nakamura, and Kei Ijichi, “Dermopathy associated with cetuximab and panitumumab: Investigation of the usefulness of moisturizers in its management,” Clinical, Cosmetic and Investigational Dermatology, vol. 10, pp. 353–361, 2017. View at Publisher · View at Google Scholar
  • Sara Campagna, Silvia Gonella, and Sara Cignola, “Skin toxicity of monoclonal antibodies,” Assistenza Infermieristica e Ricerca, vol. 36, no. 4, pp. 214–221, 2017. View at Publisher · View at Google Scholar
  • Sarah R. MacEwan, and Ashutosh Chilkoti, “From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers,” Angewandte Chemie - International Edition, vol. 56, no. 24, pp. 6712–6733, 2017. View at Publisher · View at Google Scholar
  • Julie Bogaert, Pieter-Jan Cuyle, and Eric Van Cutsem, “Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment,” Side Effects of Medical Cancer Therapy, pp. 105–119, 2018. View at Publisher · View at Google Scholar